| Identification | Back Directory | [Name]
5-Butyl-1H-pyrazole-3-carboxylic acid | [CAS]
92933-48-7 | [Synonyms]
LUF6283
5-Butyl-1H-pyrazole-3-carboxylic acid
3-butyl-1H-pyrazole-5-carboxylic acid
1H-Pyrazole-3-carboxylic acid, 5-butyl- | [Molecular Formula]
C8H12N2O2 | [MDL Number]
MFCD16620107 | [MOL File]
92933-48-7.mol | [Molecular Weight]
168.19 |
| Chemical Properties | Back Directory | [Melting point ]
166-167 °C | [Boiling point ]
385.8±30.0 °C(Predicted) | [density ]
1?+-.0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
DMSO: soluble10mg/mL (clear solution; warmed) | [form ]
powder | [pka]
15.44±0.10(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Description]
LUF6283 is a partial agonist of GPR109A/HCA2 G protein-coupled receptors (Ki = 0.55 μM in a radioligand binding assay). It stimulates [35S]-GTPγS binding and increases phosphorylation of ERK in HEK293T cells expressing GPR109A/HCA2 receptors (EC50s = 3.1 and 0.32 μM, respectively). In vivo, LUF6283 (400 mg/kg per day) reduces plasma levels of VLDL and hepatic expression of apolipoprotein B in mice. | [Uses]
LUF 6283 is a partial agonist of HCA2 and is a promising drug candidate to achieve a beneficial lipid lowering effect of niacin, ultimately treating dyslipidemic disorders. | [in vivo]
LUF6283 (C57BL/6 mice, 400 mg/kg, Oral gavage, once a day for 4 weeks) has no effect on adipose tissue ATGL/HSL expression, and significantly reduces the expression of apolipoprotein B (APOB)[1]. | [References]
[1] ZHAOSHA LI. Effects of pyrazole partial agonists on HCA2-mediated flushing and VLDL-triglyceride levels in mice[J]. British Journal of Pharmacology, 2012, 167 4: 818-825. DOI: 10.1111/j.1476-5381.2012.02039.x |
|
| Company Name: |
cjbscvictory
|
| Telephone: |
13348960310 13348960310 |
| Website: |
www.weikeqi-biotech.com/ |
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|